Dear Administrator Oz,

As members of the Heart Valve Disease Policy Task Force, a national group of 30 leaders including clinician and patient advocacy organizations, we appreciate the opportunity to comment on CMS’s proposed NCD regarding Tricuspid Valve Transcatheter Edge-to-Edge Repair (T-TEER), also known as the TriClip G4 System. We wish to emphasize the critical importance of establishing a comprehensive Medicare coverage policy that includes all FDA-approved minimally invasive transcatheter therapies for patients with symptomatic severe tricuspid regurgitation (TR).

Read full comment letter here.